Johnson & JohnsonvsXilio Therapeutics

JNJ and XLO stock compared: price, dividend, valuation and results, from SEC filings.

XLO

Xilio Therapeutics, Inc.

$7.68

Value $54M

+0.72%
XLO's page

Johnson & Johnson (JNJ) has a market value of $642B and Xilio Therapeutics (XLO) $54M. Over the last year, with dividends, JNJ moved +36.2% and XLO -26.9%. Dividend yield: JNJ 1.98%, XLO none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$642B

    XLO$54M

    JNJ is 11,828 times XLO

  • Revenue, 12 months

    JNJ$99.3B

    XLO$55M

    JNJ is 1,806 times XLO

  • Net income, 12 months

    JNJ$16.1B

    XLO-$11M

  • Operating margin

    JNJ–

    XLO-74.9%

  • ROIC

    JNJ12.4%

    XLO-67.7%

    80.1 points apart

  • P/E

    JNJ39.9

    XLO–

  • Dividend yield

    JNJ2.0%

    XLO0.0%

    2.0 points apart

  • 5-year return

    JNJ+88.6%

    XLO-97.7%

    186.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+88.6%

XLO-97.7%

010020020222023202420252026
Returns by period
PeriodJNJWith dividendsXLOWith dividends
1 year since November 18, 2025+36.2%Price +33.2%-26.9%Price -26.9%
3 years since November 17, 2023+93.6%+24.6% a yearPrice +77.8%-56.1%-24.0% a yearPrice -56.1%
5 years since November 18, 2021+88.6%+13.5% a yearPrice +64.0%-97.7%-53.1% a yearPrice -97.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonXLOXilio Therapeutics

Valuation

JNJXLO
Valuation
Price$266.44$7.68
Market value$642B$54M
Enterprise value (EV)$670B–
P/E39.9–
P/E, 5-year median21.9–
P/B7.90.8
EV/EBIT37.8–
Free cash flow yield3.2%–

Results and growth

JNJXLO
Results and growth
Revenue, 12 months$99.3B$55M
Net income, 12 months$16.1B-$11M
Free cash flow, 12 months$20.6B-$58M
Earnings per share, 12 months$6.59$0.63
Revenue growth, year on year6.1%589.9%
Revenue growth a year, past+2.7%over 5 years+589.9%over 1 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJXLO
Margins and returns on capital
Gross margin67.6%–
Operating margin–-74.9%
Net margin16.2%-20.9%
ROIC12.4%-67.7%
ROE19.7%-23.9%

Balance sheet

JNJXLO
Balance sheet
Cash$17.2B$122M
Total debt$44.7B$6.0M
Net debt / EBITDA1.1–
Interest cover18.0×–

Dividends and buybacks

JNJXLO
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or XLO

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Xilio Therapeutics?

By market value, Johnson & Johnson ($642B) is about 11,827.8 times Xilio Therapeutics ($54M), at today's prices.

How did JNJ and XLO stock do over the last 5 years?

Since November 18, 2021, JNJ's price moved +64.0% and XLO's -97.7%. With dividends: JNJ +88.6% (+13.5% a year), XLO -97.7% (-53.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or XLO?

The dividend yield at today's price is 1.98% for Johnson & Johnson and none for Xilio Therapeutics. Over the last twelve months they paid $5.28 and – per share.

Which has the higher profit margins, Johnson & Johnson or Xilio Therapeutics?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and -20.9% for Xilio Therapeutics, and the operating margin – and -74.9%. Revenue was $99.3B and $55M.

Which is the better investment, Johnson & Johnson or Xilio Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.